T1	Participants 569 693	adult patients with previously untreated AML receiving induction therapy with idarubicin, high-dose cytarabine and etoposide
T2	Participants 701 724	155 randomized patients
T3	Participants 1461 1506	AML patients receiving intensive chemotherapy
